High crude violacein production from glucose by Escherichia coli engineered with interactive control of tryptophan pathway and violacein biosynthetic pathway

Abstract

BackgroundAs bacteria-originated crude violacein, a natural indolocarbazole product, consists of violacein and deoxyviolacein, and can potentially be a new type of natural antibiotics, the reconstruction of an effective metabolic pathway for crude violacein (violacein and deoxyviolacein mixture) synthesis directly from glucose in Escherichia coli was of importance for developing industrial production process.ResultsStrains with a multivariate module for varied tryptophan productivities were firstly generated by combinatorial knockout of trpR/tnaA/pheA genes and overexpression of two key genes trpEfbr/trpD from the upstream tryptophan metabolic pathway. Then, the gene cluster of violacein biosynthetic pathway was introduced downstream of the generated tryptophan pathway. After combination of these two pathways, maximum crude violacein production directly from glucose by E. coli B2/pED + pVio was realized with a titer of 0.6 ± 0.01 g L−1 in flask culture, which was four fold higher than that of the control without the tryptophan pathway up-regulation. In a 5-L bioreactor batch fermentation with glucose as the carbon source, the recombinant E. coli B2/pED + pVio exhibited a crude violacein titer of 1.75 g L−1 and a productivity of 36 mg L−1 h−1, which was the highest titer and productivity reported so far under the similar culture conditions without tryptophan addition.ConclusionMetabolic pathway analysis using 13C labeling illustrated that the up-regulated tryptophan supply enhanced tryptophan metabolism from glucose, whereas the introduction of violacein pathway drew more carbon flux from glucose to tryptophan, thereby contributing to the effective production of crude violacein in the engineered E. coli cell factory.Electronic supplementary materialThe online version of this article (doi:10.1186/s12934-015-0192-x) contains supplementary material, which is available to authorized users.

Precise control of lycopene production to enable a fast-responding, minimal-equipment biosensor

“…Pigmented molecules are a common metabolic engineering target, whether due to their intrinsic value, their value as precursors, or just as a testbed for metabolic engineering techniques that enable simple screening (Rodrigues et al 2013, Zhao et al 2013, Fang et al 2015, Zalatan et al 2015, Fang et al 2016). However, using metabolites as reporters requires more precise control than what is necessary for most metabolic engineering applications, since small amounts of enzyme can produce visible amounts of pigment and overproduction of certain metabolites can be toxic to the cell.…”

Precision metabolic engineering: The design of responsive, selective, and controllable metabolic systems

“…Precision metabolic engineering using only sugar substrates can be used to produce metabolite outputs (such as pigments) that are visible without the use of equipment, thus enabling such biosensors to be more widely used in low-resource environments. Extensive metabolic engineering efforts have already been made to increase microbial production of pigmented metabolites such as lycopene (Alper et al, 2005a; Farmer and Liao, 2000; Yoon et al, 2006) and violacein (Fang et al, 2015; Lee et al, 2013; Rodrigues et al, 2013). By tightly controlling conditions under which these metabolites are produced, they could be used as indicators for biosensors for diverse applications.…”

Precise metabolic engineering of carotenoid biosynthesis in Escherichia coli towards a low-cost biosensor

“…There has been extensive work on the engineered overproduction of lycopene and other isoprenoids (Alper et al, 2005; Farmer and Liao, 2001; Yoon et al, 2006), as they have significant industrial value as chemicals, and isoprenoids are a precursor to yet other extremely valuable chemicals, including taxol (Ajikumar et al, 2010). Violacein has also been the subject of significant metabolic engineering efforts (Fang et al, 2015; Lee et al, 2013; Rodrigues et al, 2013), both due to the novelty and complexity of the pathway that produces it, and for its potential value as an antimicrobial or antitumor drug. In these cases, the chief goal of the metabolic engineering efforts to date has been high titer production with the downstream goal of purification.…”